Acorda completes Neuronex acquisition as diazepam nasal spray nears NDA

Acorda Therapeutics paid $6.8 million on 20 December to complete the acquisition of Neuronex and the Ardsley, New York-based company will make up to $134 million in additional milestone payments plus royalties for Neuronex's patient-friendly intranasal formulation of diazepam for the control of acute repetitive seizures (ARS).